Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...
Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...
Results from a confirmatory study show that dupilumab significantly reduces itch in patients with uncontrolled chronic spontaneous urticaria.
Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing ...
Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...
Such symptoms might be due to urticaria, commonly known as hives. Urticaria is a skin condition characterised by red, itchy welts. Although the itchiness might be temporary, the condition can recur, ...
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second ...
Refinery29 on MSN3d
What It’s Like Living With Chronic Spontaneous Hives With No Known TriggerA little over a year ago, I woke up in the middle of the night with an itchy scalp. I didn’t give it much thought, assuming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback